RDPTF (Radiopharm Theranostics) Other Operating Expense: $-6.08 Mil (TTM As of Jun. 2025)

Author: Vera Yuan Vera Yuan
Vera Yuan
Vera Yuan
Director of Data and Quant Analytics at GuruFocus
Focused on building reliable datasets, financial models, and research tools for value-minded investors. Committed to turning complex data into practical guidance for value-investing and long-term wealth.
Reviewed by: Charlie Tian Charlie Tian
Charlie Tian
Charlie Tian
Founder & CEO of GuruFocus
Dr. Charlie Tian is the founder and CEO of GuruFocus.com, a leading global investment research platform established in 2004. With a Ph.D. in physics, Dr. Tian transitioned from science to finance, applying a data-driven, disciplined approach to value investing.

What is Radiopharm Theranostics Other Operating Expense?

Radiopharm Theranostics RDPTF Other Operating Expense is $-6.08 Mil as of Jun. 2025. The stock has 5 warning signs investors should review.

Radiopharm Theranostics's Other Operating Expense for the six months ended in Jun. 2025 was $-5.41 Mil. Its Other Operating Expense for the trailing twelve months (TTM) ended in Jun. 2025 was $-6.08 Mil.

Radiopharm Theranostics's quarterly Other Operating Expense declined from Jun. 2024 ($1.85 Mil) to Dec. 2024 ($-0.67 Mil) and declined from Dec. 2024 ($-0.67 Mil) to Jun. 2025 ($-5.41 Mil).

Radiopharm Theranostics's annual Other Operating Expense increased from Jun. 2023 ($-3.97 Mil) to Jun. 2024 ($-0.85 Mil) but then declined from Jun. 2024 ($-0.85 Mil) to Jun. 2025 ($-6.09 Mil).

Radiopharm Theranostics Other Operating Expense Historical Data

* Premium members only.

The historical data trend for Radiopharm Theranostics's Other Operating Expense can be seen below:

* For Operating Data section: All numbers are indicated by the unit behind each term and all currency related amount are in USD.
* For other sections: All numbers are in millions except for per share data, ratio, and percentage. All currency related amount are indicated in the company's associated stock exchange currency.

Radiopharm Theranostics Other Operating Expense Chart

Radiopharm Theranostics Annual Data
Trend Jun22 Jun23 Jun24 Jun25
Other Operating Expense
3.22 -3.97 -0.85 -6.09

Radiopharm Theranostics Semi-Annual Data
Dec21 Jun22 Dec22 Jun23 Dec23 Jun24 Dec24 Jun25
Other Operating Expense Get a 7-Day Free Trial -3.97 -2.72 1.85 -0.67 -5.41

Radiopharm Theranostics Other Operating Expense Calculation

GuruFocus uses a standardized financial statement format for all companies. For non-financial companies, GuruFocus lists Selling, General, & Admin. Expense, , Research & Development, and Other Operating Expense under the "Total Operating Expense" section.

Other Operating Expense sometimes includes:
Restructuring, and merger
Acquisition related and other
Litigation settlement charge
Other (too numerous to list)

Some companies can and do choose to report each of these items separately. Yet, there are a variety of Other Operating Expense which are simply too numerous to list.

Other Operating Expense for the trailing twelve months (TTM) ended in Jun. 2025 adds up the semi-annually data reported by the company within the most recent 12 months, which was $-6.08 Mil.

* For Operating Data section: All numbers are indicated by the unit behind each term and all currency related amount are in USD.
* For other sections: All numbers are in millions except for per share data, ratio, and percentage. All currency related amount are indicated in the company's associated stock exchange currency.

What does a Other Operating Expense of $-6.08 Mil mean?
Radiopharm Theranostics (RDPTF) has a Other Operating Expense of $-6.08 Mil as of Jun. 2025. Other operating expenses that a company records on its income statement. View historical data on Radiopharm Theranostics and its competitors.
Is Radiopharm Theranostics' Other Operating Expense too high?
Radiopharm Theranostics' current Other Operating Expense is $-6.08 Mil.
How does Radiopharm Theranostics' Other Operating Expense compare to VRTX and REGN?
Radiopharm Theranostics' Other Operating Expense of $-6.08 Mil can be compared against companies in the Biotechnology industry. See the competitive comparison table and distribution chart on this page for a detailed peer-by-peer breakdown.
What is a good Other Operating Expense for a Biotechnology company?
A good Other Operating Expense depends on the Biotechnology industry context. However, Other Operating Expense should not be evaluated in isolation — investors should consider it alongside profitability, growth, and financial strength metrics. Use the industry distribution chart on this page to see where any company falls relative to its peers.
What does a high Other Operating Expense mean?
A high Other Operating Expense can signal that a stock is expensive relative to its fundamentals. Other operating expenses that a company records on its income statement. View historical data on Radiopharm Theranostics and its competitors. Radiopharm Theranostics's current Other Operating Expense is $-6.08 Mil. However, context matters — high-growth companies often justify higher valuations. Always evaluate alongside other metrics like GF Score™ and GF Value™.
Is Radiopharm Theranostics stock overvalued right now?
Radiopharm Theranostics (RDPTF) has a current Other Operating Expense of $-6.08 Mil. The current Other Operating Expense is $-6.08 Mil. Investors should evaluate multiple metrics — including profitability, growth, and financial strength — before making a decision.
How is Other Operating Expense calculated?
Other Operating Expense is calculated from a company's financial statements. For Radiopharm Theranostics (RDPTF), the current Other Operating Expense is $-6.08 Mil as of Jun. 2025. GuruFocus calculates this using data sourced from SEC filings and annual reports. See the calculation section and 30-year financial data on this page for the full breakdown.

Radiopharm Theranostics Business Description

Other Exchanges RADX:USARAD:Australia
Address 62 Lygon Street, Suite 1, Level 3, Carlton South, Melbourne, VIC, AUS, 3053
Radiopharm Theranostics Ltd is an Australian-based clinical-stage radiotherapeutics company targeting cancer. The company has a pipeline of approximately four licensed platform technologies, with diagnostic and therapeutic applications at both the pre-clinical and clinical stages of development. The company is engaged in research, development, and commercialization of health technologies.